Genoa Pharmaceuticals and McMaster University have partnered to characterize the in vivo advantages and potential clinical impact of Genoa's inhaled GP-101 (aerosol pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF).
Under the collaboration, Genoa will combine its expertise in aerosol drug delivery with McMaster's expertise in exploring mechanisms of pulmonary fibrosis and managing patients with IPF.
McMaster University department of medicine pathology and molecular medicine, respirology division, associate professor Martin Kolb said, "We are very interested to evaluate novel therapies such as GP-101 to better understand the molecular effects and in vivo relationship to the human disease."
Genoa founder, president and chief scientific officer Mark Surber said, "Genoa is very excited about the opportunity to collaborate with Dr. Kolb and McMaster University to better understand how inhaled GP-101 may benefit IPF patients."
